Supreme Court to tackle gene patent case

The U.S. Supreme Court is going to take up a case that could have a major impact on the patentability of genes used in diagnostics. The Supreme Court will review a case concerning Myriad Genetics ($MYGN), which won a decision from the U.S. Court of Appeals for the Federal Circuit in August. Myriad and other companies seeking novel genetic findings say that patents are important to protecting their investments in innovation. We'll see what the justices think about it. Article

 

 

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.